LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.37 -6.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.11

Max

11.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4M

676K

Pardavimai

961K

18M

P/E

Sektoriaus vid.

48.528

110.024

Pelnas, tenkantis vienai akcijai

-0.034

Dividendų pajamingumas

0.48

Pelno marža

3.67

Darbuotojai

212

EBITDA

-3M

2.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+62.95% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.48%

2.26%

Kitas uždarbis

2026-04-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-120M

248M

Ankstesnė atidarymo kaina

17.79

Ankstesnė uždarymo kaina

11.37

Naujienos nuotaikos

By Acuity

50%

50%

149 / 351 reitingas Healthcare

Simulations Plus Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-23 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

2026-02-23 22:36; UTC

Uždarbis

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

2026-02-23 22:32; UTC

Uždarbis

Woodside Energy Fiscal Year Net Profit Falls 24%

2026-02-23 23:58; UTC

Rinkos pokalbiai
Uždarbis

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

2026-02-23 23:58; UTC

Rinkos pokalbiai
Uždarbis

Global Energy Roundup: Market Talk

2026-02-23 23:47; UTC

Rinkos pokalbiai

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

2026-02-23 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

2026-02-23 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Crescent Capital Partners Owns 53% of ClearView Wealth

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

2026-02-23 23:40; UTC

Rinkos pokalbiai

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

2026-02-23 23:39; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

2026-02-23 23:27; UTC

Uždarbis

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

2026-02-23 23:24; UTC

Rinkos pokalbiai

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

2026-02-23 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

2026-02-23 22:31; UTC

Uždarbis

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

2026-02-23 22:24; UTC

Uždarbis

Viva Energy Energy & Infrastructure Ebitda A$93 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Underlying Ebitda A$700.9 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy Final Dividend 3.94 Australian Cents/Security

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

2026-02-23 22:20; UTC

Uždarbis

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Akcijų palyginimas

Kainos pokytis

Simulations Plus Inc Prognozė

Kainos tikslas

By TipRanks

62.95% į viršų

12 mėnesių prognozė

Vidutinis 19 USD  62.95%

Aukščiausias 19 USD

Žemiausias 19 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Simulations Plus Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

2

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

149 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat